CYTK – cytokinetics, incorporated (US:NASDAQ)

News

Cytokinetics (CYTK) had its "sell (d-)" rating reaffirmed by Weiss Ratings.
Cytokinetics to Announce First Quarter Results on May 5, 2026
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cytokinetics (CYTK) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $95.00 price target on the stock.
Cytokinetics (CYTK) was upgraded by Barclays PLC to "strong-buy".
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com